Merck & Co., Inc. (MRK)
| Market Cap | 247.51B |
| Revenue (ttm) | 64.24B |
| Net Income (ttm) | 19.03B |
| Shares Out | 2.48B |
| EPS (ttm) | 7.56 |
| PE Ratio | 13.20 |
| Forward PE | 11.87 |
| Dividend | $3.40 (3.37%) |
| Ex-Dividend Date | Dec 15, 2025 |
| Volume | 16,429,901 |
| Open | 101.40 |
| Previous Close | 100.89 |
| Day's Range | 99.19 - 102.09 |
| 52-Week Range | 73.31 - 105.84 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | 110.33 (+10.64%) |
| Earnings Date | Oct 30, 2025 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $110.33, which is an increase of 10.64% from the latest price.
News
Do These 3 Healthcare Stocks Need a Checkup?
Pfizer has a sizable 6.8% yield and is down nearly 60% from its 2021 highs. Bristol Myers Squibb has a 5% yield and is off its 2023 highs by nearly 40%.
Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
Vaccine makers expressed concern on Friday's decision by a U.S. advisory panel to scrap its long-standing recommendation that all infants receive a hepatitis B vaccine at birth, a shift that public he...
Is This Pharmaceutical Giant a Buy After a Major Acquisition?
Merck's newest acquisition could help it launch a promising flu candidate. Several other ongoing developments are helping paint a bright post-Keytruda picture.
These Are the 3 Hottest Stocks in the S&P 500 Heading Into the New Year. Should You Invest in Them?
New markets are opening up for Albemarle's lithium products. Recent 3M spinoff Solventum is finding its footing.
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline.
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced t...
Merck & Co., Inc. (MRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Merck & Co., Inc. (MRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Merck & Co., Inc. (MRK) Presents at Evercore 8th Annual Healthcare Conference Transcript
Merck & Co., Inc. (MRK) Presents at Evercore 8th Annual Healthcare Conference Transcript
Top 10 High-Yield Dividend Stocks For December 2025
The November 2025 high-yield dividend watchlist delivered a 2.94% gain in last month, outperforming SPY and closely trailing VYM. This watchlist blends quality and value to identify high-yield stocks ...
Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025.
These Underrated Companies Could Be "Training-Wheels" Stocks for Long-Term Wealth Builders
Merck is a high-yield drug stock with a well-supported dividend payment. Enbridge is a boring energy stock with a hefty yield.
Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%?
One of Merck's key assets has just scored a significant phase 2 win, boosting investor confidence. This adds to other recent developments that could help the company overcome its challenges.
Merck: Excellence Across The Board
Merck (MRK) demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. MRK's innovation, highlighted by Keytruda's dominance a...
Why Is Merck Stock Surging?
Merck (MRK)'s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings excee...
Merck to Participate in the Citi 2025 Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Citi 2025 Global Healthcare Conference.
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference.
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be pre...
Steven Cress' 6 Picks: 3 Dividend Income, 3 AI Growth Stocks
In volatile markets, Steve Cress recommends a barbell strategy: combining high-yield dividend stocks (MRK, PINE, OMF) with top AI growth stocks (MU, CLS, COMM). Seeking Alpha's quant system outperform...
Merck Recommends Rejection of Tutanota's “Mini-Tender” Offer
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited “mini-tender” offer, da...
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrol...
Retirement: 2 Healthcare Giants To Buy At Discounted Prices
Merck offers strong dividend growth, a robust drug pipeline, and strategic acquisitions, positioning it well beyond Keytruda's patent expiration. MRK's 3.9% dividend yield, low payout ratio, and A+ cr...
Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference 2025 Transcript
Merck & Co., Inc. ( MRK) Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM EST Company Participants Peter Dannenbaum - Vice President of Investor Relations Chirfi Guindo - Senior ...
$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield
Screening large-cap Health Care names using earnings yield plus ROTC identified five undervalued blue-chip stocks over $100B market cap. Merck, Bristol-Myers, Gilead, Pfizer, and Amgen screen as the c...
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?
Merck's newest acquisition grants it access to a highly promising medicine. That could help it overcome the challenges its two biggest franchises are facing.